Press Release: MediSapiens starts fresh growth initiatives, appoints new CEO

Helsinki, January 13, 2020

MediSapiens Ltd announced today the appointment of Mr. Nils Effertz as its new CEO (Chief Executive Officer). Former CEO Sami Kilpinen will leave his operative role in MediSapiens to pursue opportunities outside the company. We are grateful for everything Sami has meant for MediSapiens, building up a company that is at the forefront of biomedical data management and bringing in world-class clients such as Bayer Pharma, Mars Petcare, and the largest Nordic private healthcare provider.

“We are confident that Nils will lead MediSapiens into a phase of further growth and customer satisfaction. We would like to thank Sami for his outstanding service over the past 11 years. We wish him all the best for the future, both professionally and personally. Sami is committed to supporting the company in the future.“ said Petri Laine, Chairman of the Board of Directors at MediSapiens.

Nils Effertz is an experienced healthcare/technology business executive and has spent most of the past 20 years in the United States. He has held a variety of leadership positions in the health IT industry, ranging from start-up to multinational corporation and management consulting, providing highly relevant knowledge in the further commercialization of MediSapiens’ technologies. As a U.S. and German citizen, Nils looks forward to splitting his time between serving current and new clients/partners on both sides of the Atlantic, as well as at MediSapiens’ HQ in Helsinki, Finland.

“I am excited and grateful for this tremendous opportunity to lead MediSapiens into a bright future in the highly dynamic, global growth market of biomedical and health data, using our curation, analysis, and discovery solutions for actionable results. We have a fantastic team of experienced subject matter experts with a true focus on solving client challenges and I look forward to providing further opportunities to showcase our excellent software and services to clients/partners from around the world.”

MediSapiens will continue to build on its strategy to remain focused on bringing further innovations in the use of biomedical data for pharma, biobanking, life sciences, and healthcare through its range of data quality, management, and analytical solutions.

For more information, please contact:

Petri Laine, Chairman of the Board, petri.laine(at) / +358 400 909 447

MediSapiens is a global expert in the effective use of biomedical data. Established in 2009, MediSapiens provides technologies and solutions that turns data into knowledge for pharma, healthcare, research and genomic programs. Clients include Bayer Pharmaceuticals, Mars Petcare, national genomic programs and Terveystalo.